Menu
Listen as Masoud Khayyami, Acting CEO of SpectraCure, discusses milestones and events from the fourth quarter, with Erika Eliasson Ekberger as the moderator.
The report for the fourth quarter of 2023 can be found here: https://storage.mfn.se/8cdb4261-1010-4df7-aea0-1ef1056e46bb/spectracure-ab-publ-bokslutskommunike-for-januari-december-2023.pdf
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.